Navidea (NYSE:NAVB) said today it is set to receive $1 million from 2 milestone payments for its Lymphoseek injection designed for lymph nodes detection. The milestone payments come from from its U.S. distribution partner Cardinal Health (NYSE:CAH) and European partner SpePharm AG, the Dublin, Ohio-based company said. The payment from Cardinal Health is based on the sale of […]
Cardinal Health
Cardinal Health to pay up to $310m for Navidea’s LymphoSeek
Navidea (NYSE:NAVB) said today it inked a letter of intent with Cardinal Health (NYSE:CAH) to sell its Lymphoseek injection for up to $310 million. The sale includes all current FDA-approved indications, as well as future oncology diagnostic indications in North America and other related assets, Dublin, Ohio-based Navidea said. Through the deal, Navidea is slated to receive $80 […]
Si-Bone’s new CCO is ex-Baxano CEO Recupero | Personnel Moves July 6, 2016
Si-Bone’s new CCO is ex-Baxano CEO Recupero Si-Bone said yesterday it tapped ex-Baxano (NSDQ:BAXS) CEO Tony Recupero as its new chief commercial officer. Prior to moving to Si-Bone, Recupero served as president of medical device and diganostic commercialization strategy company Catalyst Performance Advisors and CEO of Baxano Inc, as well as other executive positions in the […]
Cardinal Health’s Cordis gets back in the drug-eluting stent game with Biosensors deal
Cardinal Health (NYSE:CAH) said today that its Cordis subsidiary is getting back into the drug-eluting stent game via an overseas distribution agreement with Biosensors International (PINK:BSNRY). The deal calls for Cordis to sell the BioFreedom, BioMatrix NeoFlex, BioMatrix Alpha and Chroma stents made by Biosensors in Europe, the Middle East, Australia and New Zealand. Cordis said it plans to gradually […]
Cardinal Health OKs $1B share buyback after taking a hit on tightened guidance
Cardinal Health (NYSE:CAH) said today that its board approved a $1 billion share buyback plan, after the company’s stock price took a hit last week after it tightened its earnings outlook for the rest of the year. Dublin, Ohio-based Cardinal said the share repurchasing program, which is slated to end Dec. 31, 2019, is in addition […]
Cordis touts 4-year data on Incraft AAA stent graft
Cordis Corp. said today that 4-year data from a trial of its Incraft abdominal aortic aneurysm stent graft system showed it “performed well” in patients suffering from AAAs 4 years after treatment. Data from the study was presented at the VEITHsymposium in New York City this week. The multi-center, open-label prospective Innovation trial reported a 97% […]
Cardinal Health closes $1.94b Cordis buy
Cardinal Health (NYSE:CAH) said yesterday it closed its $1.94 billion buy of Johnson & Johnson‘s (NYSE:JNJ)’s Cordis stent-making arm. The New Brunswick, N.J.-based healthcare giant announced the deal to pick up the cardiology and endovascular business from J&J in March The massive acquisition, which is worth some $1.59 billion net of tax benefits, offers annual synergies in […]
Cardinal Health to buy NaviHealth for $410m
Cardinal Health (NYSE:CAH) said it paid $290 million for a majority stake in post-acute care management firm NaviHealth, in a 4-year deal worth $410 million. The $290 million payout gives Dublin, Ohio-based Cardinal a 71% share in NaviHealth, the company said. NaviHealth’s Brentwood, Tenn.-based management team will continue to lead the business and principal investor Welsh, Carson, […]
Cardinal Health wins $1B Defense Dept. contract renewal
The U.S. Defense Dept. yesterday awarded a $1.02 billion contract renewal to Cardinal Health (NYSE:CAH). The 20-month option calls for McGaw Park, Ill.-based Cardinal Health to provide medical and surgical supplies to the Tricare military healthcare program in 29 states. It’s the 2nd of 2 options included with the original 20-month contract, the Defense Dept. said. Owens & Minor […]
Cordis releases expanded range of CTO treatment catheters
Cordis Corporation said Monday it is releasing an expanded line of catheters designed to treat and cross chronic total occlusions. The previous Johnson & Johnson (NYSE:JNJ) subsidiary, recently sold to Cardinal Health (NYSE:CAH) said it will bring the Outback Elite re-entry catheter to the U.S., Japan and Europe, and the Elitecross Support catheter to the U.S. “New and […]
J&J accepts binding offer from Cardinal Health for Cordis unit
Johnson & Johnson (NYSE:JNJ) said today that it accepted a binding offer worth about $2 billion for its Cordis stent-making arm from Cardinal Health (NYSE:CAH). The New Brunswick, N.J.-based healthcare giant said it expects the deal to close “towards the end of 2015.” The $1.94 billion deal, which is worth some $1.59 billion net of tax benefits, offers […]